Name

Camber Pharmaceuticals

Legal name

Camber Pharmaceuticals, Inc.

Website

https://camberpharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Generic pharmaceuticals
• Specialty injectables
• Oncology generics
• OTC medications
• Vertical integration API

Headquarters

HQ city

Piscataway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Rx Product Sales: Sale of generic prescription pharmaceutical products including tablets, capsules, injections, and oral solutions across multiple therapeutic categories including cardiovascular, oncology, HIV/AIDS, and specialty medications.
2. Specialty Generic Products: Sale of specialty generic medications including injectables and oncology products to hospitals, clinics, government facilities, and institutional partners.
3. Over-the-Counter (OTC) Products: Sale of OTC medications through retail partners and direct supply to consumers.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Camber Pharmaceuticals manufactures, markets, and distributes a portfolio of nearly 200 generic prescription (Rx), specialty, and over-the-counter (OTC) pharmaceutical products in the United States. The company operates three divisions—Camber Pharmaceuticals (Rx generics), Camber Specialty (injectables and oncology), and Camber Consumer Care (OTC)—supported by parent company Hetero's vertically integrated supply chain from key starting materials to active pharmaceutical ingredients to finished dosage forms.

Differentiator

Problem solved

Functional benefit

Brands

• Camber Specialty: Specialty generic medications division supporting hospitals, clinics, government facilities, and institutional partners with high-quality generic choices including injectables and oncology medications
• Camber Consumer Care

Products and services

• Camber Pharmaceuticals (Rx Generics) Primary prescription generic pharmaceutical division offering a comprehensive portfolio of cost-effective generic medications across multiple therapeutic categories including cardiovascular, oncology, antiviral, neurological, and acute care treatments. Targeted at wholesalers, distributors, hospitals, and retail pharmacies.
• Camber Specialty (Injectables and Oncology) Specialty pharmaceutical division focused on injectable and oncology medications, supporting hospitals, clinics, government facilities, and institutional partners with high-quality specialty generic choices.
• Camber Consumer Care (OTC) Over-the-counter pharmaceutical division delivering high-quality OTC medications, providing focused and reliable supply of products to retail partners for consumer purchase.
• Nitazoxanide Tablets Antiprotozoal medication indicated for treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum infections. Generic to Alinia. Available in 500mg strength, 6 count bottles.
• Cisatracurium Besylate Injection, USP Nondepolarizing neuromuscular blocker indicated as adjunct to general anesthesia for tracheal intubation and skeletal muscle relaxation during surgery, and for mechanical ventilation in ICU. Generic to Nimbex.
• Olmesartan Medoxomil and Hydrochlorothiazide Tablets Combination angiotensin II receptor blocker (ARB) and thiazide diuretic for treatment of hypertension to lower blood pressure and reduce risk of cardiovascular events. Generic to Benicar HCT.
• Plerixafor Injection Hematopoietic stem cell mobilizer used with G-CSF to mobilize stem cells for collection and subsequent autologous transplantation in non-Hodgkin's lymphoma and multiple myeloma patients. Generic to Mozobil.
• Sirolimus Oral Solution mTOR inhibitor immunosuppressant for prophylaxis of organ rejection in renal transplant patients aged 13 and older, used with cyclosporine and corticosteroids. Generic to Rapamune.
• Avanafil Tablets Phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction. Generic to Stendra. Available in 50mg, 100mg, and 200mg strengths in 30 count bottles.
• Erlotinib Tablets Kinase inhibitor for treatment of metastatic non-small cell lung cancer and pancreatic cancer (in combination with gemcitabine). Generic to Tarceva.
• Capecitabine Tablets, USP Nucleoside metabolic inhibitor for adjuvant treatment of Stage III colon cancer, perioperative rectal cancer, and treatment of metastatic colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancers. Generic to Xeloda.
• Decitabine for Injection Nucleoside metabolic inhibitor for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS. Generic to Dacogen.
• Diatrizoate Meglumine and Diatrizoate Sodium Solution, USP Diagnostic contrast agent for radiographic examination of gastrointestinal tract segments and adjunct contrast enhancement in CT imaging. Generic to Gastrografin.
• Copay Assistance Program Patient assistance program offering copay cards for select specialty medications including Dabigatran, Deferasirox, Dimethyl Fumarate, Droxidopa, Eltrombopag, Fingolimod, Lenalidomide, Nilotinib, Pirfenidone, Pomalidomide, Sapropterin, and Sodium Oxybate to reduce out-of-pocket costs.

Quantifiable outcome

• Supply service levels consistently exceed 95% for primary positions
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Hetero (Parent Company)coreStrategic or Co-development PartnerHetero is the parent company and strategic partner of Camber Pharmaceuticals. Hetero is one of the world's largest manufacturers of APIs and finished dosage forms, based in Hyderabad, India. Hetero provides Camber with vertical integration capabilities from KSMs to APIs to FDFs, R&D support with 1,200+ researchers, and access to 45 manufacturing facilities (8 dedicated to US market). Hetero employs 32,000+ associates and has presence in 140+ countries.
• Clinton FoundationminorStrategic or Co-development PartnerHetero partnered with the Clinton Foundation to supply antiretroviral (ARV) medicines to underprivileged countries, particularly in Africa.
• Healthcare Distribution PartnerscoreChannel Partner/ Reseller/ DistributorCamber works with healthcare distribution partners including major distributors to ensure reliable product availability and improve operational efficiency across the healthcare supply chain.
• Ascent PharmaceuticalsminorStrategic or Co-development PartnerAscent Pharmaceuticals, Inc. of Central Islip, New York is Camber's sister company engaged in development and manufacturing of controlled substance generics including Oxycodone, Dronabinol, and Fentanyl products.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Teva Pharmaceutical Industries: The world's largest generic drug manufacturer with a broad US portfolio across oral solids, injectables, and specialty. Directly comparable because both compete head-to-head on Day-1 generic launches and institutional/wholesaler channels, though Teva operates at vastly larger global scale.
• Sandoz (Novartis): Sandoz is one of the top global generic and biosimilar players with a large US generic portfolio, including injectables and oral solids. Highly comparable as both compete for Day-1 ANDA launches and wholesaler contracts; Sandoz also has vertically integrated manufacturing.
• Viatris: Formed from the Mylan-Upjohn combination, Viatris is a major US generics supplier with a deep portfolio spanning retail, hospital, and specialty channels. Comparable because both companies sell broad-line generics through the same wholesalers and institutional buyers.

Direct peers

• Apotex: Apotex is a privately held Canadian generic pharmaceutical manufacturer with significant US sales, vertically integrated API-to-FDF operations, and a broad product portfolio. Closely comparable to Camber given its private status, vertical integration, and aggressive ANDA pipeline.
• Aurobindo Pharma USA: US arm of India's Aurobindo Pharma, supplying generics across oral solids, injectables, and specialty. Comparable to Camber given Indian-parent vertical integration model, broad US portfolio, and shared reliance on ANDA pipelines.
• Sun Pharmaceutical Industries: Sun Pharma's US subsidiary (including the former Taro Pharmaceutical) supplies a broad range of generic Rx and specialty products. Highly comparable to Camber in business model, scale of US generics operations, and India-backed vertical integration.
• Lupin Pharmaceuticals: Lupin's US business sells generic oral solids, injectables, and specialty products with strong institutional relationships. Comparable to Camber as both are India-headquartered generic companies focused on US Day-1 launches and high-ANDA approval velocity.
• Dr. Reddy's Laboratories: Dr. Reddy's US generics arm supplies Rx, OTC, and specialty products across therapeutic categories including oncology and CNS. Comparable because both rely on parent-company vertical integration, broad ANDA pipelines, and large wholesaler relationships.
• Zydus Pharmaceuticals (USA): Zydus is the US generics subsidiary of India's Cadila Healthcare, offering oral solids, injectables, and specialty generics. Comparable to Camber given shared India-parent structure, US Day-1 launch focus, and broad institutional/retail channels.

Regional players

• Endo International: Endo's generics segment (including Par Pharmaceutical) supplies US generics, sterile injectables, and specialty products through institutional channels. Comparable to Camber in US generics and injectables exposure, though Endo has historically focused more on branded specialty and 505(b)(2) opportunities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/CamberPharma
• LinkedInlinkedin.com/company/camber-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Camber Pharmaceuticals